Skip to main content
Clinical Trials/CTRI/2022/11/047796
CTRI/2022/11/047796RecruitingPhase 2

Evaluation of efficacy of Phalatrikadi Ghana Vati in patients of Non-Alcoholic Fatty Liver Disease,through reverse pharmacology approach.

Dr Piyush Chaudhary0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1. Ultrasonography (USG) abdomen suggestive of NAFLD with or without symptoms like pain in right upper quadrant/epigastric region of the abdomen, feeling of nausea, and vomiting, loss of appetite, burning sensation in the abdomen.
  • 2.Liver function tests showing raised alanine transaminases (ALT) or aspartate transaminases (AST) levels raised above the normal limits (40IU/L) up to 300 IU/

Exclusion Criteria

  • 1. Patients unwilling to participate in study
  • 2. Patients with a history of alcohol intake exceeding 20 g/day (Alcohol consumption history shall be separately obtained from the patients and family)
  • 3. Patients testing positive for markers of other viral hepatitis

Investigators

Sponsor
Dr Piyush Chaudhary

Similar Trials